ArticlePharmacoEconomics - open2024

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers.

Diana Beatriz Bayani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.